ArticleCancer medicine2026
The Steroidal Profile Modulates Adaptive Immune Response and Prognosis in Adrenocortical Carcinoma: Analysis of TCR and BCR Repertoires.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Adrenocortical carcinoma (ACC) is a rare and aggressive malignant neoplasm with limited therapeutic options and an often poor prognosis. A deeper understanding of its interaction with the immune system is essential for the advancement of personalized treatment strategies, particularly in light of the tumor heterogeneity of hormone production. ACC tumors can be classified into high steroid phenotype (HSP) and low steroid phenotype (LSP) subtypes, which exhibit distinct biological behaviors and immunological microenvironments. However, the composition and prognostic significance of T-cell and B-cell receptor (TCR and BCR) repertoires in these subtypes remain largely unknown. In this study, we demonstrate that steroid phenotype is a key determinant of the adaptive immune response and clinical outcomes in ACC. LSP tumors exhibit significantly higher lymphocytic infiltration and greater repertoire diversity, reflecting a more immunogenic tumor microenvironment, despite the significant expression of immune evasion and exhaustion genes. These findings provide new insights into how the hormonal environment shapes the immunobiology of ACC, reveal possible mechanisms of immune escape in cortisol-producing tumors, and highlight the prognostic relevance of immune repertoire characteristics. Our results support the integration of TCR/BCR profiling with steroid phenotyping to improve risk stratification and inform the design of precision immunotherapeutic strategies for ACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.